EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting notch signaling pathway in esophageal cancer: from molecular insights to therapies

Sangita Bhattacharyya, Hindole Ghosh, Ameer Hamza, Bernhard Biersack, Gregory N Gan, Prateek Sharma, Prasad Dandawate

Oncology Reviews · 08.07.2026 · 20

DOI: 10.3389/or.2026.1709219 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Oncology Reviews, online erschienen am 08.07.2026. Verfasst von Sangita Bhattacharyya und 6 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Biology, University of Kansas Medical Center, Kansas City, KS, United States. Die Arbeit nennt 252 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Esophageal cancer (EC) is a major digestive cancer with a poor 5-year survival rate of less than 20%. EC incidence is projected to increase by 35% in the US by 2025. The two subtypes of EC with distinct histology, esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC), exhibit deregulation of various oncogenic signaling pathways, distinct pathological features at diagnosis, and distinct mutation profiles. Hence, these cancers require different treatment approaches for their clinical management. ESCC is more prevalent globally, while EAC is prevalent in Western countries, including Europe, North America, and Australia. Notably, two-thirds of US EC cases are EAC. Drug resistance, faster progression, and recurrence are significant problems of EC. Hence, there is a need to identify novel targets in EC progression. Cancer stem cells (CSCs) are a small population of cells in tumors that can self-renew and are responsible for EMT, drug resistance, and recurrence in EC. These serve as attractive targets for drug development and EC treatment. CSCs express surface markers and use the notch, Hedgehog, Hippo, and Wnt-β-catenin pathways to regulate their growth and survival. We are also including a mutation and expression analysis of PANCAN and EC patients for genes/proteins in the notch signaling pathway, using the cBioPortal and TCGA databases. EC was ranked second among cancers with mutations in the notch pathway. Here, we outline the role of notch signaling in EC biology and its inhibitors for EC treatment.

Schlagwörter

Stichwörter der Autor:innen

esophageal adenocarcinomaesophageal canceresophagusinhibitorsnotch signaling

Autor:innen und Institutionen

  • Cancer Biology, University of Kansas Medical Center, Kansas City, KS, United States.
  • Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, United States.
  • Organic Chemistry Laboratory, University of Bayreuth, Bayreuth, Germany.
  • Radiation Oncology, University of Kansas Medical Center, Kansas City, KS, United States.
  • Gastroenterology and Hepatology, Kansas City Veterans Administration Hospital, Kansas City, MO, United States.

Zitieren

APA

Bhattacharyya, S., Ghosh, H., Hamza, A., Biersack, B., Gan, G. N., Sharma, P., & Dandawate, P. (2026). Targeting notch signaling pathway in esophageal cancer: from molecular insights to therapies. Oncology Reviews, 20. https://doi.org/10.3389/or.2026.1709219

Vancouver

Bhattacharyya S, Ghosh H, Hamza A, Biersack B, Gan GN, Sharma P, et al. Targeting notch signaling pathway in esophageal cancer: from molecular insights to therapies. Oncology Reviews. 2026;20. doi:10.3389/or.2026.1709219

BibTeX
@article{Bhattacharyya2026,
  author = {Bhattacharyya, Sangita and Ghosh, Hindole and Hamza, Ameer and Biersack, Bernhard and Gan, Gregory N and Sharma, Prateek and Dandawate, Prasad},
  title = {Targeting notch signaling pathway in esophageal cancer: from molecular insights to therapies},
  journal = {Oncology Reviews},
  year = {2026},
  volume = {20},
  doi = {10.3389/or.2026.1709219}
}
Kostenlos starten →